Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
neurodegenerative diseases
Biotech
Sanofi signs 2nd biotech deal of the day
Sanofi is paying Adel $80 million in cash, with the total deal potentially reaching up to $1.04 billion, plus royalties.
Gabrielle Masson
Dec 15, 2025 5:50pm
Merck KGaA becomes latest partner for Flagship’s Valo Health
Nov 20, 2025 6:30am
Voyager sets sail on neuro research trek with Transition Bio
Nov 10, 2025 5:23pm
FDA rejects Biohaven approval request, triggering cost cutting
Nov 5, 2025 4:02am
Roche signs $2B pact to pilot Manifold's shuttles to the brain
Nov 3, 2025 8:45am
Alector halves staff after GSK-partnered antibody fails in ph. 3
Oct 22, 2025 11:23am
